Israel Englander’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-493,633
Closed -$47.9M 4866
2019
Q3
$47.9M Sell
493,633
-169,216
-26% -$16.9M 0.08% 321
2019
Q2
$67.9M Sell
662,849
-31
-0% -$3.35K 0.1% 217
2019
Q1
$75.5M Buy
+662,880
New +$48.7M 0.11% 213
2018
Q4
Sell
-72,538
Closed -$3.96M 4420
2018
Q3
$3.96M Sell
72,538
-28,595
-28% -$1.96M ﹤0.01% 1973
2018
Q2
$8.37M Buy
101,133
+77,434
+327% +$5.98M 0.01% 1443
2018
Q1
$1.58M Buy
+23,699
New +$1.37M ﹤0.01% 2457
2017
Q4
Sell
-242,952
Closed -$21.7M 4238
2017
Q3
$21.7M Sell
242,952
-292,679
-55% -$22.2M 0.03% 752
2017
Q2
$32M Buy
535,631
+92,638
+21% +$5.18M 0.06% 482
2017
Q1
$23.6M Sell
442,993
-573,633
-56% -$34.1M 0.04% 590
2016
Q4
$50.7M Buy
+1,016,626
New +$54.5M 0.11% 257
2016
Q3
Sell
-310,809
Closed -$15.9M 3773
2016
Q2
$15.9M Buy
310,809
+270,909
+679% +$11.6M 0.04% 635
2016
Q1
$1.18M Buy
39,900
+21,044
+112% +$664K ﹤0.01% 2097
2015
Q4
$854K Buy
+18,856
New +$988K ﹤0.01% 2378
2015
Q3
Sell
-147,320
Closed -$8.88M 3877
2015
Q2
$8.88M Buy
+147,320
New +$9.74M 0.02% 1053

Israel Englander's ONCE Position: Q4 2019 in Review

Israel Englander sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 493,633 shares — an estimated $47.9M sold.

Israel Englander first reported a position in ONCE in Q2 2015 and held it in 14 quarters. The position peaked at $75.5M in Q1 2019. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.

  • Israel Englander reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Israel Englander sold 493,633 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $47.9M.
  • Israel Englander first reported a position in Spark Therapeutics, Inc. Common Stock in Q2 2015 and held it in 14 quarters.
  • Israel Englander's Spark Therapeutics, Inc. Common Stock position peaked at $75.5M in Q1 2019.
  • 0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Millennium Management's 13F filing for Q4 2019, filed 14 Feb 2020.